Control
Nov 22 2022 |
et al., NCT04969991 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2 |
| 120% higher mortality (p=1), 240% higher ventilation (p=1), and 240% higher progression (p=1). Very small early terminated RCT showing no significant differences with varespladib treatment. | ||